Compare Ascendis Pharma A/S (ASND) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Dollar General Corp. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Dollar General Corp. trades at $118.92 (market cap $26.23B). The key difference: Dollar General Corp. is the larger of the two by market cap, and Dollar General Corp. pays a 1.98% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DG | |
|---|---|---|
Market Cap | $17.74B | $26.23B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $156.26 |
52-Week Low | $163.32 | $95.94 |
Enterprise Value | $18.11B | $40.68B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Dollar General (DG) trades at $118.92, up 2.76% today, with a neutral technical signal and bearish moving averages. The stock shows strong valuation metrics with a P/E of 16.82 and P/S of 0.61, supported by three consecutive quarterly earnings beats. Revenue grew to $40.61B in 2025, though net margins compressed to 2.77%. Positive news highlights margin expansion and back-to-school initiatives, while cash flow improved to $395M net.
Outlook remains cautiously optimistic with a $128.45 consensus price target implying 8% upside. Risks include margin pressure from inflation and competitive threats. Analyst consensus is 52% Buy, but weak consumer sentiment and technical resistance near $120 may limit near-term gains. Debt reduction trends and dividend coverage provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
